Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESIDE: Enzalutamide + Docetaxel in mCRPC
NCT02288247Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2014
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Started Dec 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02288247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288247.